Tenofovir continues to suppresses hepatitis B virus for eight years

Most people with chronic hepatitis B who are
treated with tenofovir for eight years continued to maintain viral suppression,
researchers reported at the American
Association for the Study of Liver Diseases (AASLD) Liver Meeting earlier this month in
Boston, United States. Serological response rates continued to increase
over time and kidney and bone-related side-effects remained